Patents Issued in June 14, 2022
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11357761
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11357762
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating fabry patients having renal impairment
    Patent number: 11357763
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11357764
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11357765
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Compositions and methods for treating cancer
    Patent number: 11357766
    Abstract: The present invention includes composition and methods for treating cancers comprising administering to a subject a pharmaceutical composition comprising Pimavanserin or derivatives thereof in an amount sufficient to treat the reproductive cancer in the subject and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 14, 2022
    Assignee: Texas Tech University System
    Inventors: Sanjay K. Srivastava, Sharavan Ramachandran
  • Compounds for use in treating depression and migraine
    Patent number: 11357767
    Abstract: The invention relates to amide-derivatives of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid for use in a treatment for preventing or suppressing symptoms associated with mood disorders, headaches and migraine. The compounds of the invention can be used to treat any subject suffering from a mood disorder, headaches and/or migraine but can specifically be used to treat a mood disorder, headaches and/or migraine in patients suffering from a mitochondrial disease.
    Type: Grant
    Filed: November 22, 2018
    Date of Patent: June 14, 2022
    Assignee: Khondrion IP B.V.
    Inventors: Johannes Albertus Maria Smeitink, Julien David Beyrath
  • Methods for treating NASH and for preventing NASH-induced HCC
    Patent number: 11357768
    Abstract: Disclosed are methods of treating non-alcoholic steatohepatitis (NASH) and methods of preventing NASH-induced hepatocellular carcinoma (HCC), such methods including administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime (BGP15), alone or in combination with a inhibitor of the interleukin-6 receptor transsignaling response, particularly gp130Fc.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 14, 2022
    Assignee: N-GENE RESEARCH LABORATORIES, INC.
    Inventors: Mark Anthony Febbraio, Jozsef Mandl
  • Drug combinations for reducing cell viability and/or cell proliferation
    Patent number: 11357769
    Abstract: Provided herein is a combination of agents for reducing cell viability and/or cell proliferation. The combination comprises an FGFR4 inhibitor and an EGFR inhibitor.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 14, 2022
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Anand Selvaraj, Peter Smith
  • Method of treating immunoglobulin light chain amyloidosis
    Patent number: 11357770
    Abstract: The present invention relates to the use of substituted quinoline compounds for treating immunoglobulin light chain (LC) amyloidosis (AL), especially cardiotoxicity associated with immunoglobulin LC AL. In particular, the substituted quinoline compounds useful in the treatment of cardiac LC amyloidosis are 5,7-dihalo-8-hydroxyquinoline derivatives, especially 5,7-dichloro-8-hydroxyquinoline derivatives.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 14, 2022
    Assignee: Alterity Therapeutics Limited
    Inventors: Luisa Diomede, Mario Salmona, Giampaolo Merlini
  • Methods of preventing or treating flavivirus virus infections and methods of inhibiting the entry of flvivirus, enterovirus or lentivirus into host cells
    Patent number: 11357771
    Abstract: A method of preventing or treating a subject suffering from a flavivirus infection by administering an effective amount of berbamine or its analogue to the subject, berbamine has a structure of Formula (I), wherein the flavivirus infection is caused by Japanese encephalitis virus, Zika virus or Dengue virus. A method of inhibiting the entry of a flavivirus, an enterovirus and/or a lentivirus into host cells includes contacting the host cells with an effective amount of berbamine of its analogue, berbamine has a structure of Formula (I), wherein the flavivirus is Japanese encephalitis virus, Zika virus or Dengue virus.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: June 14, 2022
    Assignees: City University of Hong Kong, 6J Biotechnology (Hong Kong) Limited
    Inventors: Jianbo Yue, Lihong Huang
  • Methods for the treatment of abnormal involuntary movement disorders
    Patent number: 11357772
    Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: June 14, 2022
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: David Stamler, Michael Huang
  • Methods and compositions for enhancing immune response to vaccination
    Patent number: 11357773
    Abstract: Compositions and methods are described in which the topical application of a toll-like receptor 7 agonist or a toll-like receptor 9 agonist at or near a subdermal vaccination site provides an enhanced response to the vaccination. The enhanced response can be an elevated antibody titer relative to an untreated but vaccinated subject, and/or development of cross-species immunity to species not present in the vaccinating composition.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: June 14, 2022
    Assignee: VERSITECH LIMITED
    Inventors: Fan Ngai Hung, Jinxia Zhang, Kai Wang Kelvin To, Johnson Yiu-Nam Lau, Kwok Yung Yuen
  • Use of a quinoline sulfonyl compound for treatment of inflammation, inflammatory disorders, autoimmune disorders and malaria
    Patent number: 11357774
    Abstract: The present application relates to uses of 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline (VR23) or optionally a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of malaria or for treatment of a disease, disorder or condition treatable by reducing or inhibiting the secretion of a pro-inflammatory cytokine and/or reducing myeloperoxidase such as inflammation, an inflammatory disorder or autoimmune disease.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: June 14, 2022
    Inventors: Hoyun Lee, Amanda Durkin
  • Combination therapies comprising apremilast and Tyk2 inhibitors
    Patent number: 11357775
    Abstract: Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 14, 2022
    Assignee: Celgene Corporation
    Inventors: Peter Henry Schafer, Robert Plenge, Mary Adams, Lisa Beebe, Gilles Buchwalter, Tiffany Carr, Te-chen Tzeng
  • Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
    Patent number: 11357776
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 14, 2022
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: Brian North, Steven Quayle
  • Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)
    Patent number: 11357777
    Abstract: The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of Nonalcoholic Steatohepatitis (NASH).
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: June 14, 2022
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: G-Yoon Jamie Im, Mark G. Currie, James Edward Sheppeck, Paul Allan Renhowe, Pei Ge, Jaime L. Masferrer
  • Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3
    Patent number: 11357778
    Abstract: The present invention relates to the treatment or prevention of skeletal disorders, at particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: June 14, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ PARIS CITÉ, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, IMAGINE
    Inventors: Laurence Legeai-Mallet, Arnold Munnich, Patricia Busca, Florent Barbault
  • G1T38 superior dosage regimes
    Patent number: 11357779
    Abstract: A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: June 14, 2022
    Assignee: G1 Therapeutics, Inc.
    Inventors: Andrew Beelen, Jay Copeland Strum
  • Methods and compositions relating to the inhibition of IP6K1
    Patent number: 11357780
    Abstract: The technology described herein is directed to methods of treating lung infections and/or lung inflammation (e.g, pneumonia) by inhibiting IP6K1.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: June 14, 2022
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventor: Hongbo R. Luo
  • Non-catalytic substrate-selective, p38?-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
    Patent number: 11357781
    Abstract: Compounds that inhibit p38? MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: June 14, 2022
    Assignees: University of Maryland, Baltimore, The United States of America as represented by The Department of Veterans Affairs
    Inventors: Paul S. Shapiro, Alexander D. MacKerell, Jr., Jeffrey D. Hasday
  • Treprostinil administration by inhalation
    Patent number: 11357782
    Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: June 14, 2022
    Assignee: United Therapeutics Corporation
    Inventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
  • Conjugate of finasteride with peptide
    Patent number: 11357783
    Abstract: A composition for preventing hair loss and, more specifically, to a compound having a structure in which finasteride and a peptide are linked through a covalent bond and a pharmaceutical composition or a cosmetic composition for preventing hair loss or promoting hair growth comprising the same. The compound having a structure in which finasteride and a peptide are linked through a covalent bond is excellent in physiological activities such as hair loss improvement, hair growth promotion, cell growth promotion, etc., is excellent in stability in water and skin permeation, and thus can be effectively used as a composition for preventing hair loss and promoting hair growth.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 14, 2022
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Use of migalastat for treating Fabry disease in pregnant patients
    Patent number: 11357784
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease. Certain methods treat a pregnant patient with a therapeutically effective dose of migalastat or a salt thereof. Other methods treat a patient of childbearing potential with a therapeutically effective dose of migalastat or a salt thereof. Also described are the successful outcomes of pregnancies during which the pregnant patient is treated with migalastat.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 14, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Jay Barth
  • Compositions for use in the reduction of nociception in infants and young children
    Patent number: 11357785
    Abstract: The present invention relates to compositions comprising 6?-sialyllactose (6?SL) and lacto-N-tetraose (LNT), for use in the reduction of nociception in an infant or in a young child. The compositions are in particular useful in reducing abdominal pain, such as pain associated with infantile colic, irritable bowel syndrome (IBS) and/or recurrent abdominal pain (RAP), and consequently also contribute to reducing the crying periods and to improving the quality of sleep and the general quality of life of the infants and young children.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 14, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Sami Damak, Norbert Sprenger, Francis Foata
  • Synthetic disugar hydrocarbons as natural analogs to control microbial behaviors
    Patent number: 11357786
    Abstract: Synthetic disaccharide hydrocarbons (DSHs) that reactive bacterials swarming motility and inhibit bacterial adhesion and biofilm formation. A library of DSHs were tested in several experiment for the impact on various Pseudomonas aeruginosa populations and compared against existing compounds to determine efficacy and utility. Certain DSHs were also to determine the ability to clear bacteria in a mouse pneumonia model.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: June 14, 2022
    Assignees: Syracuse University, The Research Foundation for the State University of New York
    Inventors: Yan-Yeung Luk, Guirong Wang
  • Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent
    Patent number: 11357787
    Abstract: To provide a technique for selecting a target cell producing a target substance that specifically binds to a desired cell membrane protein more rapidly and efficiently. A substrate 1 having a plurality of microwells 2 is provided. A first cell 3 expressing a target cell membrane protein on its surface is allowed to adhere to each of the microwells 2. One or two second cells 5 as a candidate of a target cell are introduced into each microwell 2, and are allowed to coexist with the first cell 3 in the microwell 2, and target substance 6 secreted by the second cell 5 is brought into contact with the first cell 3. A microwell 2 including the first cell 3 to which the target substance 6 binds is identified. The second cell 5 as the target cell is recovered from the identified microwell 2. One example of the target substance 6 is an antibody. Visualization may be performed by adding a label substance 7.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: June 14, 2022
    Assignee: NB HEALTH LABORATORY CO., LTD.
    Inventors: Masami Ashida, Yuji Urushibata, Kiyoshi Takayama
  • Nuclear paraspeckle assembly transcript 1 as therapeutic targeting in neurodegeneration
    Patent number: 11357788
    Abstract: The present disclosure provides a method of reducing neurodegeneration and/or TDP43 associated aggregation, comprising knocking down the expression of Nuclear Paraspeckle Assembly Transcript 1 (NEAT1) or LncRNA NEAT1. Also provided are methods for screening a candidate agent that reduces neurodegeneration and/or TDP43 associated aggregation in a cell, treating or preventing a neurodegenerative disorder, delaying or preventing the onset of a neurodegenerative disorder or reducing a risk for developing a neurodegenerative disorder in a subject and determining whether a subject is suffering from, or at a risk of developing a neurodegenerative disorder, comprising measuring the presence of cytoplasmic NEAT1 in a biological sample, wherein the presence is indicative of the risk of developing a neurodegenerative disorder.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: June 14, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Hung-Chih Kuo, Yi-Ying Wu
  • Strategy to increase anti-viral, anti-microbial, and anti-fungal defense
    Patent number: 11357789
    Abstract: Disclosed herein are compositions and methods for inducing, promoting, or enhancing an immune response in a subject. For example, the disclosed compositions and methods can be used prophylactically to prevent viral/microbial infections or therapeutically to treat acute infections. In some embodiments, the disclosed method involves administering to the subject a composition comprising in vitro transcribed (IVT) RNA comprising short interspersed nuclear elements (SINEs), such as Alu repeats. In some embodiments, the disclosed compositions and methods can be used to induce, promote, or enhance any immune response in a subject, including an anti-viral, anti-microbial, anti-fungal, or anti-parasite response. In some embodiments, the disclosed compositions can be administered to any mucosal barrier, such as lungs or intestines, e.g. to enhance an innate immune response against a virus or pathogen.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: June 14, 2022
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventor: Hana Totary-Jain
  • Sterile formulation comprising a stable phosphorothioate oligonucleotide
    Patent number: 11357790
    Abstract: A composition including a phosphorothioate oligonucleotide and at least one fatty acid and/or at least one emulsifying agent, where the composition is sterile and where the composition includes at least one agent including a thiol group and at least one phosphate compound, and the composition can be an ophthalmic composition. The present invention also relates to a method for obtaining the same and to the therapeutic use thereof.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: June 14, 2022
    Assignee: GENE SIGNAL INTERNATIONAL SA
    Inventors: Éric Viaud, Antoine Ferry, Carla Missiaen, Jo Vercammen
  • Compositions and methods for the treatment of sinus disease and disorders
    Patent number: 11357791
    Abstract: A composition comprising kappa-carrageenan and a carrier solution, wherein the carrier solution is an isotonic solution, and methods of use thereof in the treatment of diseases or conditions of the upper airways.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: June 14, 2022
    Assignee: ENT TECHNOLOGIES PTY LTD
    Inventor: Sam Barbalatt
  • Method of administration and treatment
    Patent number: 11357792
    Abstract: Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: June 14, 2022
    Assignee: Dyvve Biosciences, Inc.
    Inventor: Ryan Beal
  • Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
    Patent number: 11357793
    Abstract: Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: June 14, 2022
    Assignee: Sapna Life Sciences Corporation
    Inventor: James Lorne Henry
  • Preparations for controlled-release of hypochlorous acid
    Patent number: 11357794
    Abstract: Provided are anti-microbial compositions that include an aqueous solution of hypochlorous acid encapsulated in a nanoparticle that allows for controlled release of hypochlorous acid. Also provided are methods of making and using such compositions.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 14, 2022
    Assignee: WIAB WAFER INNOVATION AB
    Inventor: Geir Hermod Almås
  • Combination immunotherapies for treatment of cancer
    Patent number: 11357795
    Abstract: Described herein are compositions and methods for treating a disease, particularly a cancer, with an immune checkpoint modulatory agent and a strain of an Arbovirus or a strain of an Alphavirus. Also provided herein are also methods for combination therapy comprising administration of an immune checkpoint modulatory agent, tumor antigen primed dendritic cells and an Alphavirus or an Arbovirus.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 14, 2022
    Assignee: PRIMEVAX IMMUNO-ONCOLOGY, INC.
    Inventor: Bruce W. Lyday
  • Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
    Patent number: 11357796
    Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric receptor (e.g., CAR or TCR) genetically modified T cell immunotherapy. Some aspects of the disclosure relate to methods of determining an effective dose of a T cell immunotherapy comprising polyfunctional T cells prior to administration to the patient.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 14, 2022
    Assignee: KITE PHARMA, INC.
    Inventors: John M. Rossi, Adrian I. Bot
  • Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
    Patent number: 11357797
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: June 14, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Mesenchymal stem cell-derived exosome
    Patent number: 11357798
    Abstract: The present invention relates to mesenchymal stem cell-derived microparticles having activity that promotes the growth of corneal epithelial stem cells and/or corneal epithelial cells, activity that maintains corneal epithelial stem cells in an undifferentiated state or promotes the formation of colonies thereby, and function that protects corneal epithelium.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 14, 2022
    Assignees: OSAKA UNIVERSITY, ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Kohji Nishida, Ryuuhei Hayashi, Yoichi Honma, Toru Okubo, Shun Shibata
  • Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
    Patent number: 11357799
    Abstract: Described herein are compositions and techniques related to generation and therapeutic application of cardiosphere-derived cells (CDCs) and CDC-derived exosomes. These cells and their secreted vesicles contain a unique milieu of biological factors, including cytokines, growth factors, transcription factors, nucleic acids including non-coding nucleic acids such as microRNAs, that serve to initiate and promote many therapeutic effects. Exosomes and their “cargo” contents, such as microRNAs can favorably modulate apoptosis, inflammation and fibrosis in the injured heart. Thus, CDC-derived exosomes represent a novel “cell-free” therapeutic candidate for tissue repair.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: June 14, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Eduardo Marban, Mark Amin Aminzadeh
  • Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies
    Patent number: 11357800
    Abstract: Without limitation, a method for preventing and/or treating neuropathic pain in a subject/patient comprising administering a therapeutically effective amount of exosomes derived and isolated from mammalian cells to the subject/patient and a method of treating cancer in a subject/patient in need thereof, comprises administering a combination comprising a therapeutically effective amount of exosomes derived and isolated from mammalian cells and a chemotherapeutic agent.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: June 14, 2022
    Assignee: Henry Ford Health System
    Inventors: Zhenggang Zhang, Yi Zhang, Michael Chopp
  • Methods for treating autism spectrum disorder and associated symptoms
    Patent number: 11357801
    Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: June 14, 2022
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: James Adams, Dae-Wook Kang, Rosa Krajmalnik-Brown
  • Oral delivery compositions for improved gut barrier protection and immunity in mammals
    Patent number: 11357802
    Abstract: Compositions containing probiotics and a nitric oxide precursor such as L-arginine to enhance nitric oxide production in animals and methods for improving immunity, gut barrier functions, and gut health and treating gastroenteritis and mucositis in animals using same.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: June 14, 2022
    Assignee: Vets Plus, Inc.
    Inventors: Daniel J. DuBourdieu, Rajiv Lall, Ajay Srivastava
  • Probiotic compositions for production of dopamine
    Patent number: 11357803
    Abstract: The present invention is directed to synbiotic compositions of probiotic strains and prebiotics, along with uses thereof for targeted human and animal applications, for example, in promoting health and well-being and/or treating therapeutic conditions. The present invention is also directed to methods of probiotic selection and detection of strains with the ability to produce neurochemicals in the gastrointestinal tract of a subject, providing a microbial endocrinology-based mechanism and approach for optimization of synbiotic delivery of a probiotic with a neurochemical precursor. Still further the present invention is directed to industrial applications for production of dopamine utilizing methods and media suitable for the same.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: June 14, 2022
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Mark Lyte, Daniel Nicholas Villageliu
  • Application of oncolytic viruses as immunostimulants for treatment of tumors and/or cancers
    Patent number: 11357804
    Abstract: Provided is the use of selectively replicating oncolytic viruses in the preparation of immunostimulants for treatment of tumors and/or cancers, wherein the oncolytic viruses do not carry exogenous immunoregulatory genes.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: June 14, 2022
    Assignee: HANGZHOU CONVERD CO., LTD.
    Inventors: Ronghua Zhao, Yanjun Zheng, Fang Hu
  • Compositions and methods for treating the eye
    Patent number: 11357805
    Abstract: The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of mucin from and/or in the cornea, and methods of using the compositions to treat the eye.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: June 14, 2022
    Assignee: Johnson & Johnson Surgical Vision, Inc.
    Inventors: Wen-Hwa Ting Li, Khalid Mahmood, Ramine Parsa, Manpreet Randhawa, Mingqi Bai, Kenneth T. Holeva
  • Method of isolating sphingolipids from cordyceps and their use
    Patent number: 11357806
    Abstract: A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from Cordyceps, in particular from wild-type Cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities. A method of treating a subject suffering from an inflammatory disease like an autoimmune disease or an allergic disease includes administering sphingolipids isolated from Cordyceps, in particular from wild-type Cordyceps. A method of treating a subject suffering from an inflammatory disease includes administering certain sphingolipids to the subject.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: June 14, 2022
    Assignee: Macau University of Science and Technology
    Inventors: Zhi-Hong Jiang, Jing-Rong Wang, Jia-Ning Mi, Junping Kou, Yuwei Han, Yingqiong Xu
  • Method of preparing cannabis extracts
    Patent number: 11357807
    Abstract: The invention relates to a method of preparing cannabis extracts, including shatter, budder and wax extracts. The extraction method can provide a high quality and pure extraction product of THC from cannabis plant material, as either a shatter, wax or budder end extraction product. The extracted product is free of polar cannabis plant material, chlorophyll and residual solvents, has a high concentrate of THC, and can be used for dabbing, vaping or smoking consumption by a user. Suitable solvents for the method are gases selected from the group consisting of propane, butane or iso-butane, and the preferred solvent is propane. A key step of the method of the present invention is recovering solvent under atmospheric vacuum and, therefore, obtaining an extraction product that is purified of solvent and has no solvent.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 14, 2022
    Assignee: Cold Baked LLC
    Inventor: Joshua Hindi
  • Method of preparing cannabis extracts
    Patent number: 11357808
    Abstract: The invention relates to a method of preparing cannabis extracts, including shatter, budder and wax extracts. The extraction method can provide a high quality and pure extraction product of THC from cannabis plant material, as either a shatter, wax or budder end extraction product. The extracted product is free of polar cannabis plant material, chlorophyll and residual solvents, has a high concentrate of THC, and can be used for dabbing, vaping or smoking consumption by a user. Suitable solvents for the method are gases selected from the group consisting of propane, butane or iso-butane, and the preferred solvent is propane. A key step of the method of the present invention is recovering solvent under atmospheric vacuum and, therefore, obtaining an extraction product that is purified of solvent and has no solvent.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: June 14, 2022
    Assignee: Cold Baked LLC
    Inventor: Joshua Hindi
  • Herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using spp
    Patent number: 11357809
    Abstract: This disclosure describes herbal preparations for the stimulation of hair growth, control of hair fall, control of dandruff, and control of dandruff-related infections thereof, using herbaceous plants, Ageratum spp. Processes for preparing the herbal preparations and methods for using them are also disclosed. Such an herbal preparation using plants, Ageratum spp. can be utilized as an efficient hair care solution in a wide range of hair growth related problems of humans in a cost-effective manner.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: June 14, 2022
    Assignee: GE Nutrients, Inc.
    Inventors: Vaiyapuri Ramalingam Prabavathy, Ramasamy Varadarajan Venkatesh, Jith Veeravalli
  • Compositions with purified cocoon silk peptide fiber and refined seed oil having synergistic effects for improving memory, focus, and cognitive function, and related methods
    Patent number: 11357810
    Abstract: Compositions and methods for improving memory, cognitive performance, providing neuroprotection, and treating neurological disease or symptoms thereof are described. The compositions comprise a synergistic combination of purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil, and preferably Blueberry Extract, and may be administered as a dietary supplement.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: June 14, 2022
    Assignee: Brain Health Holding LLC
    Inventors: Gregory Cumberford, Troylyn Ball, Marcus Goddard